NR3C2 and myocardial infarction: However, clinical trials of MR antagonists also suggest that MI classification, heart failure status and timing of MR antagonist administration remain important factors in determining post-MI cardiovascular outcomes (Bulluck et al., 2019; Chen et al., 2021; Mares et al., 2022).